| |
Sept. 25 - 26, 2024 | San Diego, CA Learn out of the box strategies for MSLs to engage with KOLs and HCPs post-pandemic, successful approaches to establishing medical communications plans ahead of a launch. Complimentry Passes Available! Learn More. .png)
|
|
Today’s Big NewsAug 8, 2024 |
|
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria. 
|
|
| By Annalee Armstrong,James Waldron The confetti is still flying from Eli Lilly’s party celebrating the approval of Alzheimer’s med, but the company is yet again facing the harsh reality of the neurodegenerative disease with the failure of an early tau-targeting med. |
|
|
|
By Annalee Armstrong After a year defined by pipeline cuts, the departure of its CEO and layoffs, Exscientia will merge into Recursion, creating one company that has 10 clinical readouts to look forward to over the next 18 months. |
By Nick Paul Taylor Merck & Co.’s TIGIT program has suffered another setback. Months after shuttering a phase 3 melanoma trial, the Big Pharma has terminated a pivotal lung cancer study after an interim review revealed efficacy and safety problems. |
By Gabrielle Masson After an FDA rejection last year, Aldeyra Therapeutics has scored a clinical win for dry eye drug reproxalap, which significantly reduced ocular discomfort in a new phase 3 study. |
|
Maximize Your Brand Exposure From brand awareness to lead generation, our tailored marketing solutions help you achieve your objectives. Get noticed, start conversations, and drive demand with Fierce Biotech. Learn more now. 
|
|
By James Waldron Cullinan Therapeutics was impressed enough with Harbour BioMed’s bispecific immune activator that it handed over $25 million last year for the drug's U.S. rights. But, having taken a peek at phase 1 data, Cullinan has had second thoughts. |
By Nick Paul Taylor Mattress Liquidators has turned Entero Therapeutics white as a sheet. The creditor ordered Entero to repay its loan, prompting the biotech to lay off staff from the CEO down and race to find a way out of its predicament. |
By Darren Incorvaia Aminoglycosides are cheap and effective antibiotics that can come with a heavy price—hearing loss. Commonly used in developing countries and for infants in neonatal intensive care, just a few days of treatment can cause these powerful drugs to build up in the inner ear and kill the sensory hair cells that enable hearing, resulting in irreversible damage. |
By Darren Incorvaia Primarily a respiratory virus, our understanding of SARS-CoV-2 has been hampered by an inability to study the pathogen in its natural habitat—a living, breathing human lung. Thankfully, lung biologist Sandra Leibel, M.D., has been working with “mini-lungs” derived from human stem cells since 2012. |
By Darren Incorvaia Charles River Laboratories has reported its second-quarter earnings, with the CRO seeing revenue decline from $1.06 billion in the second quarter of last year to $1.03 billion. Demand for the company’s services is likely to continue its downward trajectory through the rest of the year, according to an Aug. 7 release. |
By Nick Paul Taylor The FDA has taken Bristol Myers Squibb to task for making false or misleading claims about the efficacy of Krazati on the website for the KRAS cancer drug. |
By Fraiser Kansteiner Late Wednesday, the FDA granted approval to Amneal’s Crexont—formerly known as IPX203—which is an oral, extended-release formulation of the common Parkinson’s disease drugs carbidopa/levodopa (CD/LD). The capsule, which contains a mix of immediate-release CD/LD granules and extended-release LD-coated beads, is expected to launch in the U.S. in September. |
By Zoey Becker The cost-effectiveness regulator recommended government funding for the groundbreaking gene editing therapy in one of its two approved indications. |
Fierce podcasts Don’t miss an episode |
| This week on “Podnosis” we're discussing a new payment model that could affect thousands of hospitals across the country. It's called TEAM, and it stands for Transforming Episode Accountability Model. It's a mandatory bundled payment program that covers five common procedures. |
|
|---|
|
|
|
Thursday, September 5, 2024 | 12pm ET / 9am PT Liquid biopsy is emerging as a revolutionary technology, offering swift and precise diagnostics. However, it still faces key challenges. Join us to learn more about the collaborative efforts of SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center, and AstraZeneca that are aimed at addressing disparities in cancer care. Register now. 
|
|
Whitepaper This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
Whitepaper Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
